Logo image of WAY

WAYSTAR HOLDING CORP (WAY) Stock Fundamental Analysis

NASDAQ:WAY - Nasdaq - US9467841055 - Common Stock

37.47  +0.11 (+0.29%)

After market: 37.47 0 (0%)

Fundamental Rating

4

Taking everything into account, WAY scores 4 out of 10 in our fundamental rating. WAY was compared to 39 industry peers in the Health Care Technology industry. Both the profitability and the financial health of WAY get a neutral evaluation. Nothing too spectacular is happening here. WAY has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year WAY has reported negative net income.
WAY had a positive operating cash flow in the past year.
WAY Yearly Net Income VS EBIT VS OCF VS FCFWAY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 0 50M -50M 100M

1.2 Ratios

The Return On Assets of WAY (-1.16%) is better than 86.49% of its industry peers.
Looking at the Return On Equity, with a value of -1.72%, WAY belongs to the top of the industry, outperforming 86.49% of the companies in the same industry.
With a decent Return On Invested Capital value of 1.94%, WAY is doing good in the industry, outperforming 78.38% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for WAY is below the industry average of 6.36%.
The last Return On Invested Capital (1.94%) for WAY is above the 3 year average (1.69%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -1.16%
ROE -1.72%
ROIC 1.94%
ROA(3y)-1.01%
ROA(5y)N/A
ROE(3y)-2.27%
ROE(5y)N/A
ROIC(3y)1.69%
ROIC(5y)N/A
WAY Yearly ROA, ROE, ROICWAY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 1 -1 2 -2

1.3 Margins

With an excellent Operating Margin value of 11.95%, WAY belongs to the best of the industry, outperforming 91.89% of the companies in the same industry.
With a decent Gross Margin value of 66.52%, WAY is doing good in the industry, outperforming 67.57% of the companies in the same industry.
Industry RankSector Rank
OM 11.95%
PM (TTM) N/A
GM 66.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
WAY Yearly Profit, Operating, Gross MarginsWAY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 0 20 40 60

More info and screens

5

2. Health

2.1 Basic Checks

WAY has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for WAY remains at a similar level compared to 1 year ago.
Compared to 1 year ago, WAY has a worse debt to assets ratio.
WAY Yearly Shares OutstandingWAY Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 50M 100M 150M
WAY Yearly Total Debt VS Total AssetsWAY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 1B 2B 3B 4B

2.2 Solvency

An Altman-Z score of 2.85 indicates that WAY is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of WAY (2.85) is better than 72.97% of its industry peers.
WAY has a debt to FCF ratio of 13.92. This is a negative value and a sign of low solvency as WAY would need 13.92 years to pay back of all of its debts.
WAY has a Debt to FCF ratio of 13.92. This is comparable to the rest of the industry: WAY outperforms 56.76% of its industry peers.
A Debt/Equity ratio of 0.40 indicates that WAY is not too dependend on debt financing.
WAY has a Debt to Equity ratio (0.40) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF 13.92
Altman-Z 2.85
ROIC/WACC0.22
WACC8.82%
WAY Yearly LT Debt VS Equity VS FCFWAY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 500M 1B 1.5B 2B

2.3 Liquidity

WAY has a Current Ratio of 2.29. This indicates that WAY is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 2.29, WAY is doing good in the industry, outperforming 64.86% of the companies in the same industry.
A Quick Ratio of 2.29 indicates that WAY has no problem at all paying its short term obligations.
With a decent Quick ratio value of 2.29, WAY is doing good in the industry, outperforming 64.86% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.29
Quick Ratio 2.29
WAY Yearly Current Assets VS Current LiabilitesWAY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for WAY have decreased strongly by -16.59% in the last year.
The Revenue has grown by 12.22% in the past year. This is quite good.
EPS 1Y (TTM)-16.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%133.06%
Revenue 1Y (TTM)12.22%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%21.72%

3.2 Future

Based on estimates for the next years, WAY will show a very strong growth in Earnings Per Share. The EPS will grow by 74.21% on average per year.
The Revenue is expected to grow by 11.92% on average over the next years. This is quite good.
EPS Next Y203.32%
EPS Next 2Y118.23%
EPS Next 3Y74.21%
EPS Next 5YN/A
Revenue Next Year18.97%
Revenue Next 2Y13.11%
Revenue Next 3Y11.92%
Revenue Next 5YN/A

3.3 Evolution

WAY Yearly Revenue VS EstimatesWAY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 200M 400M 600M 800M 1B
WAY Yearly EPS VS EstimatesWAY Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8 1

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

WAY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 44.04, WAY can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of WAY indicates a somewhat cheap valuation: WAY is cheaper than 72.97% of the companies listed in the same industry.
WAY is valuated expensively when we compare the Price/Forward Earnings ratio to 24.11, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 44.04
WAY Price Earnings VS Forward Price EarningsWAY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50 -100

4.2 Price Multiples

72.97% of the companies in the same industry are more expensive than WAY, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of WAY is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 71.95
EV/EBITDA 25.09
WAY Per share dataWAY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15

4.3 Compensation for Growth

WAY's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
WAY's earnings are expected to grow with 74.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y118.23%
EPS Next 3Y74.21%

More info and screens

0

5. Dividend

5.1 Amount

WAY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

WAYSTAR HOLDING CORP

NASDAQ:WAY (1/17/2025, 8:00:02 PM)

After market: 37.47 0 (0%)

37.47

+0.11 (+0.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)N/A N/A
Inst Owners52.38%
Inst Owner Change0%
Ins Owners1.15%
Ins Owner Change1.42%
Market Cap6.45B
Analysts84.29
Price Target36.38 (-2.91%)
Short Float %9.77%
Short Ratio4.67
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)176.35%
Min EPS beat(2)29.95%
Max EPS beat(2)322.74%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)6.83%
Min Revenue beat(2)6.23%
Max Revenue beat(2)7.44%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)17.91%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)22.37%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 44.04
P/S 7.12
P/FCF 71.95
P/OCF 55.37
P/B 2.11
P/tB N/A
EV/EBITDA 25.09
EPS(TTM)-0.36
EYN/A
EPS(NY)0.85
Fwd EY2.27%
FCF(TTM)0.52
FCFY1.39%
OCF(TTM)0.68
OCFY1.81%
SpS5.27
BVpS17.74
TBVpS-6.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.16%
ROE -1.72%
ROCE 2.46%
ROIC 1.94%
ROICexc 2%
ROICexgc 44.83%
OM 11.95%
PM (TTM) N/A
GM 66.52%
FCFM 9.89%
ROA(3y)-1.01%
ROA(5y)N/A
ROE(3y)-2.27%
ROE(5y)N/A
ROIC(3y)1.69%
ROIC(5y)N/A
ROICexc(3y)1.71%
ROICexc(5y)N/A
ROICexgc(3y)44.14%
ROICexgc(5y)N/A
ROCE(3y)2.14%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF 13.92
Debt/EBITDA 4.09
Cap/Depr 13.88%
Cap/Sales 2.96%
Interest Coverage 250
Cash Conversion 38.61%
Profit Quality N/A
Current Ratio 2.29
Quick Ratio 2.29
Altman-Z 2.85
F-Score5
WACC8.82%
ROIC/WACC0.22
Cap/Depr(3y)9.99%
Cap/Depr(5y)N/A
Cap/Sales(3y)2.57%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%133.06%
EPS Next Y203.32%
EPS Next 2Y118.23%
EPS Next 3Y74.21%
EPS Next 5YN/A
Revenue 1Y (TTM)12.22%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%21.72%
Revenue Next Year18.97%
Revenue Next 2Y13.11%
Revenue Next 3Y11.92%
Revenue Next 5YN/A
EBIT growth 1Y58.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year167.6%
EBIT Next 3Y46.21%
EBIT Next 5YN/A
FCF growth 1Y-64.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-49.86%
OCF growth 3YN/A
OCF growth 5YN/A